Preview

Вестник аритмологии

Расширенный поиск

СИНДРОМ УДЛИНЁННОГО ИНТЕРВАЛА QT И ПРОБЛЕМЫ БЕЗОПАСНОСТИ ПСИХОФАРМАКОТЕРАПИИ

Аннотация

Рассматриваются особенности проявления приобретенного синдрома удлиненного интервала QT, развивающегося на фоне применения психофармакотерапевтических препаратов.

Об авторе

И. Н. Лиманкина
Санкт-Петербургская психиатрическая больница №1 им. П.П.Кащенко
Россия


Список литературы

1. Buckley N, Sanders P. Cardiovascular adverse effects of antipsychotic drugs // Drug Safety 2000;23(3):215-228

2. Brown S. Excess mortality of schizophrenia, a metaanalysis.// Br J Psychiatry 1997;171:502-508

3. O’Brien P and Oyebode F. Psychotropic medication and the heart. // Advances in Psychiatric Treatment. 2003;9:414-423

4. Abdelmawla N and Mitchel AJ. Sudden cardiac death and antipsychotics drugs. // Advances in Psychiatric Treatment 2006;12:35-44;100-109

5. Herxheimer A, Healy D. Arrythmias and sudden death in patients taking antipsychotic drugs.// BMI 2002; 325:12531254

6. FDA issues public health advisory for antipsychotic drugs used for treatment of behavioral disorders in elderly patients (FDA talk Paper) Rochvill (MD): US Food and Drug Adminstration,2006

7. Schwartz PJ. The Long QT Syndrome. // Vol.7, Futura Publishing Company, Inc., Armonk, NY, 1997

8. Schwartz PJ, Spazzolini C, Crotti L et al. The Jervell and Lange-Nielsen Sundrome: natural history, molecular basis and clinical outcome. // Circulation 2006;113:783-790

9. Бутаев Т.Д., Трешкур Т.В., Овечкина М.А. и др. Врождённый и приобретённый синдром удлинённог интервала QT (учебно-методическое пособие) Инкарт. Санкт-Петербург, 2002

10. Camm AJ. Drug-Induced Long QT Syndrome // Vol.16, Futura Publishing Company, Inc., Armonk, NY, 2002

11. Van de Kraats GB, Slob J, Tenback DE. [Reduction of prolonged QTc-interval related risks with neuropharma-cological drugs. Recommendations for clinical practice].// Tijdschr Psychiatr 2007;49(1):43-47

12. Glassman AH and Bigger JR. Antipsychotic drugs: prolonged QTc interval, torsade de pointes and sudden death.// American Journal of Psychiatry 2001;158:1774-1782

13. Vieweg WVR. Neu-generation antipsychotic drugs and QTc-interval prolongation.// Primary Care Companion J Clin Psychiatry 2003;5:205-215

14. Mehtonen OP, Aranki K, Malkonen L et al. A survey of sudden death associated with the use of antipsychotics or antidepressant drugs: 49 cases in Finland.// Acta Psychiat-rica Scandinavica 1991;84:58-64

15. Ray WA, Meredith S, Thapa PB et al. Antipsychotics and the risk of sudden cardiac death.// Archives of General Psychiatry 2001;58:1161-1167

16. Straus SMJM, Bleumink GS, Dieleman JP et al. Antipsychotics and the risk of sudden cardiac death.// Archives of Internal Medicine 2004;164:1293-1297

17. Trenton AJ, Currier GW, Zwemer FL. Fatalities associated with therapeutic use and overdose of atypical antipsychotics // CNS Drugs 2003;17:307-324

18. Victor W, Wood M. Tricyclic Antidepressants, QT Interval and Torsade de Pointes.// Psychosomatics 2004;45:371-377

19. Thorstrand C. Clinical features in poisoning by tricyclic antidepressants with special reference to the ECG.// Acta Med Scan 1976;199:337-344

20. Wilens TE, Biederman J, Baldessarini RJ et al. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents.// J Am Acad Child Adolesc Psychiatry 1995;35:1474-1480

21. Riddle MA, Geller B, Ryan N. Another sudden death in a child treated with desipramine.// J Am Acad Child Ad-olesc Psychiatry 1993;32:792-797

22. Varley CK, McClellan J. Case study: two additional sudden deaths with tricyclic antidepressants.// J Am Acad Child Adolesc Psychiatry 1997;36:390-394

23. Oesterheld J. TCA cardiotoxicity: the latest.// J Am Acad Child Adolesc Psychiatry 1996;34:1460-1468

24. Swanson JR, Jones GR, Krasselt W et al. Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms.// J Forensic Sci 1997;42:335-339

25. Haverkamp W, Breithardt G, Camm AJ et al. The potential for QT prolongation and proarrhythmia by non-an-tiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology // Eur Heart J 2000;21(5):1216-1231

26. Ogata N, Narahashi T. Block of sodium channels by psychotropic drugs in single quinea-pig cardiac myocytes // Br J Pharmacol 1989;97(3):905-913

27. Crumb WJ, Beasley C, Thornton A et al. Cardiac ion channel blocking profile of olanzapine and other antipsychotics. Presented at the 38th American College of Neuropsychopharmacology Annual Meeting; Acapulco, Mexico; December 12-16,1999

28. Jo SH, Youm JB, Lee CO et al. Blocade of the HERG human cardiac K+channel by the antidepressant drug amitriptyline.// Br J Pharmacol 2000;129:1474-1480

29. Kupriyanov VV, Xiang B, Yang L, Deslauriers R. Lithium ion as a probe of Na+channel activity in isolated rat hearts: a multinuclear NMR study.// NMR Biomed 1997;10:271-276

30. Kiesecker C, Alter M, Kathofer S et al. Atypical tetracyclic antidepressant maprotiline is an antagonist at cardiac HERG potassium channels.// Naunyn Schmiedebergs Arch Pharmacol 2006;373(3):212-220

31. Tarantino P, Appleton N, Lansdell K. Effect of trazodone on HERGchannel current and QT-interval.// Eur J Pharmacol 2005;510(1-2):75-85

32. Jow F, Tseng E, Maddox T et al. Rb+ efflux through functional activation of cardiac KCNQ1/mink channels by the benzodiazepine R-L3 (L-364,373).// Assay Drug Dev Technol 2006;4(4):443-450

33. Rajamani S, Eckhardt LL, Valdivia CR et al. Drug-induced long QT syndrome: HERG K+ channel block and disruption of protein trafficking by fluoxetine and nor-fluoxetine.// Br J Pharmacol 2006;149(5):481-489

34. Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease.// J Clin Psychiatry 2005;66 Suppl 6:5-10

35. Shamgar L, Ma L, Schmitt N et al. Calmodulin is essential for cardiac IKS channel gating and assembly: impaired function in long-QT mutations.// Circ Res 2006;98(8):1055-1063

36. Hull BE, Lockwood TD. Toxic cardiomyopaty: the effect of antipsychotic-antidepressant drugs and calcium on myocardial protein degradation and structural integrity.// Toxicol Appl Pharmacol 1986;86(2):308-324

37. Reilly JG, Ayis SA, Ferrier IN et al. QTc-interval abnormalties and psychotropic drugs therapy in psychiatric patients.// Lancet 2000;355(9209):1048-1052

38. Andreassen OA, Steen VM. [Pharmacogenetics and tailored drug treatment in schizophrenia].// Tidsskr Nor Laegeforen 2006;126(18):2400-2402

39. Kutscher EC, Carnahan R. Common CYP450 interactions with psychiatric medicines: A brief review for the primary care physician.//S D Med 2006;59(1):5-9

40. Kropp S, Lichtinghagen R, Winterstein K et al. Cytochrome P450 2D6 and 2C19 polymorphisms and length of hospitalization in psychiatry.// Clin Lab 2006;52(5-6):237-240

41. Daniel WA. The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms.// Expert Opin Drug Metab Toxicol 2005;1(2):203-217

42. Kootstra-Ros JE, Van Weelden MJ, Hinrichs JM et al. Therapeutic drug monitoring of antidepressants and cytochrome P450 genotyping in general practice.// J Clin Pharmacol 2006;46(11):1320-1327

43. Андреев Б.В., Лиманкина И.Н. Проблема интервала QT в психиатрической практике.// Медицина ХХ век 2006;4:41-44


Рецензия

Для цитирования:


Лиманкина И.Н. СИНДРОМ УДЛИНЁННОГО ИНТЕРВАЛА QT И ПРОБЛЕМЫ БЕЗОПАСНОСТИ ПСИХОФАРМАКОТЕРАПИИ. Вестник аритмологии. 2008;52(52):66-71.

For citation:


Limankina I.N. LONG QT INTERVAL SYNDROME AND PROBLEMS OF SAFETY OF PSYCHOPHARMACOTHERAPY. Journal of Arrhythmology. 2008;52(52):66-71. (In Russ.)

Просмотров: 204


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1561-8641 (Print)
ISSN 2658-7327 (Online)